Business Context and Reporting Period
Company: HUTCHMED (China) Ltd
Filing Type: Form 6-K (Supplemental and Updated Disclosures)
Date: June 21, 2021
Reporting Period: Unaudited financial data for the three months ended March 31, 2021, compared to the same period in 2020.
Purpose: This filing provides supplemental disclosures required for a proposed listing on the Main Board of The Stock Exchange of Hong Kong Limited. It updates the 2020 Annual Report with recent developments, financial results, and expanded industry and business information.
Key Financial Metrics (Three Months Ended March 31, 2021)
| Metric | 2021 (US$) | 2020 (US$) | Change |
|---|---|---|---|
| Total Revenues | 81.6 million | 51.6 million | +58.1% |
| Net Loss (Company) | (41.1 million) | (16.1 million) | Widened |
| Loss Per Share | (0.06) | (0.02) | - |
| Operating Expenses | 144.8 million | 84.1 million | +72.2% |
| R&D Expenses | 57.1 million | 30.5 million | +87.0% |
| Cash & Short-term Investments | 396.1 million | 435.2 million (Dec 31, 2020) | -8.9% (QoQ) |
| Net Cash Used in Operating Activities | (22.4 million) | (1.8 million) | - |
Revenue Breakdown
- Oncology/Immunology: $21.7 million (+227.3% YoY). Driven by Elunate sales ($13.4 million) and the launch of Sulanda ($5.5 million).
- Other Ventures: $59.9 million (+33.2% YoY). Driven by increased prescription drug sales and consumer health products.
Material Changes vs. Prior Period
- Revenue Growth: Significant increase driven by the commercial launch of Sulanda (surufatinib) in January 2021 and accelerated sales of Elunate (fruquintinib) following the company's assumption of marketing responsibilities in October 2020.
- Expense Surge: R&D expenses rose 87.0% due to the expansion of clinical activities in the U.S. and Europe, specifically for fruquintinib, surufatinib, HMPL-689, and HMPL-306. Selling expenses increased 121.0% due to marketing costs for Sulanda.
- Net Loss Expansion: The net loss attributable to the company more than doubled to $41.1 million, primarily due to the substantial increase in R&D and operating expenses outpacing revenue growth.
- Strategic Disposal: Entered into an agreement to sell its entire investment in Hutchison Baiyunshan (non-consolidated joint venture) for approximately $169 million, expected to generate a disposal gain of $80-90 million. This marks an exit from the over-the-counter drug arena to focus on oncology.
- Capital Raise: Completed a private placement of $100 million of shares to Baring Asia Private Equity Fund VII in April 2021.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Focus Shift: Management is pivoting resources entirely toward the discovery and development of novel therapies in oncology and immunology, exiting the OTC market via the Hutchison Baiyunshan sale.
- Pipeline Progress:
- Savolitinib: NDA under priority review in China for NSCLC; global Phase III studies planned.
- Surufatinib: Launched in China; U.S. NDA rolling submission completed in April 2021.
- Fruquintinib: Global Phase III (FRESCO-2) enrollment targeted for late 2021.
- Future Expenses: The company expects to incur significant expenses, particularly R&D, for the foreseeable future as it expands development and seeks regulatory approvals.
Risks and Contingencies
- PCAOB Inspection Risk: The company's auditors are located in Hong Kong/China, where the PCAOB is currently unable to conduct full inspections. Failure to meet enhanced listing standards by January 1, 2022, could result in delisting from Nasdaq.
- Development Risk: Drug development is highly speculative; candidates may fail to gain regulatory approval or become commercially viable.
- Liquidity: The company has incurred significant net operating cash outflows and relies on cash reserves, equity offerings, and potential milestone payments to fund operations.
- Joint Venture Dependence: A significant portion of "Other Ventures" revenue and cash flow depends on the performance and dividend distributions of non-consolidated joint ventures.
Key Facts for Investor Verification
- Listing Status: Verify the status of the proposed Hong Kong Main Board listing and the associated Global Offering.
- Disposal Completion: Monitor the regulatory approval and completion of the Hutchison Baiyunshan sale to confirm the estimated $80-90 million gain.
- PCAOB Compliance: Track developments regarding the Holding Foreign Companies Accountable Act and the company's ability to satisfy PCAOB inspection requirements to avoid U.S. delisting.
- Cash Burn Rate: Assess the sustainability of the current cash position ($396.1 million) against the accelerating R&D burn rate ($57.1 million in Q1 alone).
- Commercial Execution: Verify the sales trajectory of Sulanda and Elunate in China following the company's assumption of full marketing control.